Congenital Fetal Heart Block
Authors:
- Anna L. DavidADAnna L. David
- Ifat AtaullahIAIfat Ataullah
- Rob YatesRYRob Yates
- Ian SullivanISIan Sullivan
- Peter CharlesPCPeter Charles
- David WilliamsDWDavid Williams
- 1 August 2010
- journal article
- case report
- Published by Wolters Kluwer Health in Obstetrics & Gynecology
- Vol. 116 (2) , 543-547
Abstract
Congenital heart block affects 2% of all mothers with anti-Ro/La antibodies, can cause heart failure in utero, and has a 20% mortality rate in the first 3 years of life. Maternal fluorinated steroids to prevent or reverse congenital heart block can cause pregnancy complications. Intravenous immunoglobulin (IVIG) has been given with maternal steroids to prevent the recurrence of congenital heart block, although its efficacy is unproven. We report the use of IVIG to prevent progression of 2:1 congenital heart block with intermittent complete heart block. After two maternal infusions of IVIG (0.4 g/kg) at 31 weeks of gestation, the fetal heart rate reverted to long periods of sinus rhythm, which was sustained until postnatal life. Our case supports investigating IVIG in the prevention or treatment of this life-threatening condition.Keywords
This publication has 13 references indexed in Scilit:
- The cerebroplacental Doppler ratio predicts postnatal outcome in fetuses with congenital heart blockJournal of Perinatology, 2008
- Utility of Cardiac Monitoring in Fetuses at Risk for Congenital Heart BlockCirculation, 2008
- Intravenous immunoglobulin and placental transport of anti‐Ro/La antibodies: Comment on the letter by Kaaja and JulkunenArthritis & Rheumatism, 2004
- Prevention of recurrence of congenital heart block with intravenous immunoglobulin and corticosteroid therapy: Comment on the editorial by Buyon et alArthritis & Rheumatism, 2003
- Risk of congenital complete heart block in newborns of mothers with anti-Ro/SSA antibodies detected by counterimmunoelectrophoresis: A prospective study of 100 womenArthritis & Rheumatism, 2001
- Comparison of treatment with fluorinated glucocorticoids to the natural history of autoantibody-associated congenital heart block: Retrospective review of the research registry for neonatal lupusArthritis & Rheumatism, 1999
- Neonatal lupus erythematosus: results of maternal corticosteroid therapyObstetrics & Gynecology, 1999
- Averse Effects of Intravenous Immunoglobulin TherapyClinical Pediatrics, 1996
- Autoantibody-Associated Congenital Heart Block: Outcome in Mothers and ChildrenAnnals of Internal Medicine, 1994
- Anti–Ro/SS‐A and Anti–La/SS‐B autoantibody levels in relation to systemic lupus erythematosus disease activity and congenital heart blockArthritis & Rheumatism, 1992